X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs DISHMAN PHARMA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD DISHMAN PHARMA LUPIN LTD/
DISHMAN PHARMA
 
P/E (TTM) x 19.8 25.1 78.8% View Chart
P/BV x 2.7 3.3 80.0% View Chart
Dividend Yield % 0.9 0.7 140.9%  

Financials

 LUPIN LTD   DISHMAN PHARMA
EQUITY SHARE DATA
    LUPIN LTD
Mar-17
DISHMAN PHARMA
Mar-16
LUPIN LTD/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,750374 467.4%   
Low Rs1,384129 1,073.3%   
Sales per share (Unadj.) Rs387.4197.8 195.9%  
Earnings per share (Unadj.) Rs56.621.2 267.1%  
Cash flow per share (Unadj.) Rs76.834.7 221.3%  
Dividends per share (Unadj.) Rs7.502.00 375.0%  
Dividend yield (eoy) %0.50.8 60.2%  
Book value per share (Unadj.) Rs298.9179.9 166.2%  
Shares outstanding (eoy) m451.5880.69 559.6%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x4.01.3 317.9%   
Avg P/E ratio x27.711.9 233.1%  
P/CF ratio (eoy) x20.47.2 281.4%  
Price / Book Value ratio x5.21.4 374.7%  
Dividend payout %13.29.4 140.4%   
Avg Mkt Cap Rs m707,51320,306 3,484.3%   
No. of employees `00016.80.8 2,025.6%   
Total wages/salary Rs m28,4955,355 532.1%   
Avg. sales/employee Rs Th10,418.319,252.7 54.1%   
Avg. wages/employee Rs Th1,697.06,459.5 26.3%   
Avg. net profit/employee Rs Th1,523.02,064.1 73.8%   
INCOME DATA
Net Sales Rs m174,94315,961 1,096.1%  
Other income Rs m1,065265 401.3%   
Total revenues Rs m176,00816,226 1,084.7%   
Gross profit Rs m44,9314,103 1,095.0%  
Depreciation Rs m9,1221,091 836.4%   
Interest Rs m1,525944 161.5%   
Profit before tax Rs m35,3492,334 1,514.8%   
Minority Interest Rs m-720-   
Prior Period Items Rs m831 7,500.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m9,785624 1,569.1%   
Profit after tax Rs m25,5751,711 1,494.6%  
Gross profit margin %25.725.7 99.9%  
Effective tax rate %27.726.7 103.6%   
Net profit margin %14.610.7 136.4%  
BALANCE SHEET DATA
Current assets Rs m119,54211,018 1,085.0%   
Current liabilities Rs m61,2069,517 643.1%   
Net working cap to sales %33.39.4 354.6%  
Current ratio x2.01.2 168.7%  
Inventory Days Days76110 68.8%  
Debtors Days Days9035 258.0%  
Net fixed assets Rs m131,66016,304 807.5%   
Share capital Rs m903161 559.6%   
"Free" reserves Rs m134,07312,907 1,038.8%   
Net worth Rs m134,97614,516 929.9%   
Long term debt Rs m56,4784,189 1,348.1%   
Total assets Rs m266,07329,805 892.7%  
Interest coverage x24.23.5 696.5%   
Debt to equity ratio x0.40.3 145.0%  
Sales to assets ratio x0.70.5 122.8%   
Return on assets %10.28.9 114.3%  
Return on equity %18.911.8 160.7%  
Return on capital %19.317.5 109.9%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m81,8854,952 1,653.7%   
Fx outflow Rs m21,506697 3,086.4%   
Net fx Rs m60,3784,255 1,419.1%   
CASH FLOW
From Operations Rs m41,1482,786 1,476.7%  
From Investments Rs m-25,287-1,529 1,653.9%  
From Financial Activity Rs m4,332-941 -460.3%  
Net Cashflow Rs m20,193316 6,382.0%  

Share Holding

Indian Promoters % 46.6 61.4 75.9%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 3.7 305.4%  
FIIs % 31.9 12.7 251.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 22.1 45.7%  
Shareholders   98,259 46,261 212.4%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   SANOFI INDIA  ABBOTT INDIA  FRESENIUS KABI ONCO.  CIPLA  ASTRAZENECA PHARMA  

Compare LUPIN LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Feb 22, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - PLETHICO PHARMA COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS